This is a single-centre, double-blind, randomised, multiple ascending dose, placebo-controlled study including four cohorts. All cohorts will have treatment regimens consisting of 15-day once daily dosing and a follow-up visit 21 days after last dosing. Participants will undergo a Screening period beginning up to 28 days prior to randomisation/dose administration.
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.